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Anthracyclines, most powerful anticancer agents, suﬀer from their cardiotoxic eﬀects, which may be due to the induction of
oxidative stress. Carvedilol, a third-generation, nonselective β-adrenoreceptor antagonist, possesses both reactive oxygen species
(ROS) scavenging and ROS suppressive eﬀe c t s .I ts h o w e dp r o t e c t i v ee ﬀects against daunorubicin- (DNR-) induced cardiac toxicity
by reducing oxidative stress and apoptosis. This study therefore was designed to examine the eﬀects of carvedilol on DNR-induced
cardiomyopathic rats, focused on the changes of left ventricular function, cardiac ﬁbrosis, and hypertrophy. Carvedilol increased
survival rate, prevented systolic and diastolic dysfunction, and attenuated myocardial ﬁbrosis and hypertrophy. DNR alone treated
rats showed upregulated myocardial expression of ANP, PKC-α,O P N ,a n dT G F - β1 and downregulation of GATA-4 in comparison
with control, and treatment with carvedilol signiﬁcantly reversed these changes. The results of the present study add the available
evidences on the cardioprotection by carvedilol when associated with anthracyclines and explain the mechanisms underlying the
beneﬁts of their coadministration.
1.Introduction
Today, anthracyclines (doxorubicin, daunorubicin (DNR),
epirubicin, and idarubicin) are among the most powerful
drugs used for the treatment of oncologic diseases both in
childhoodandadulthood[1].Regrettably,theirclinicaluseis
limited by the occurrence of dose-related cardiotoxicity [2].
This toxicity has elicited a large number of studies aimed
at understanding both the mechanisms involved and the
possible method to circumvent it.
Anthracycline cardiotoxicity has been traditionally asso-
ciated with oxidative stress-induced injury with a catalytic
involvement of free cellular iron [3]. For many years, it
has been believed that reactive oxygen species- (ROS-)
induced degenerative changes are the primary hallmarks of
anthracycline cardiomyopathy [4, 5]. Pathological studies
on experimental animal models and human endomyocardial
biopsies have shown that anthracycline-induced cardiomy-
opathy is characterized by histological alterations consisting
in multiple areas of interstitial ﬁbrosis associated with the2 ISRN Pharmacology
presence of cardiomyocytes with vacuolar degeneration or
compensatory hypertrophy. Necrotic cardiomyocytes with
cellular inﬁltration, stromal edema with myocardial ﬁbers
dissociation, and the presence of polymorphonuclear cells
can also be observed [6–8].
Carvedilol, a third-generation, nonselective β-adreno-
receptor antagonist that also possesses α1-adrenergic block-
ing property, has been shown to provide greater beneﬁt than
traditional β-adrenoreceptor antagonists in chronic heart
failure because of its antioxidant, antiapoptotic, antiinﬂam-
matory, and antiﬁbrotic properties [9]. A number of preclin-
ical studies have demonstrated that carvedilol possesses both
ROS scavenging and ROS suppressive eﬀects compared to
other β-adrenoreceptor antagonists in various experimental
models of cardiac dysfunction and ischemia reperfusion
[10–12]. Moreover, we and other investigators have recently
reported that carvedilol prevents the development of cardiac
toxicity induced by anthracyclines in rats [13], in the isolated
perfused rat heart [14], and in patients receiving anthracy-
clines [15].Inourpreviousreport,carvedilolshowedprotec-
tive eﬀects against DNR-induced cardiac toxicity by reducing
oxidative stress and apoptosis [13]. Nevertheless, it remains
to be determined whether carvedilol can reduce cardiac
ﬁbrosis and hypertrophy in DNR-induced cardiomyopathic
rats by its antioxidative and antiapoptotic eﬀects. This study
thereforewasdesignedtoexaminetheeﬀectsofcarvedilolon
DNR-inducedcardiomyopathicratsandfocusedonstudying
the changes of left ventricular function, cardiac ﬁbrosis, and
hypertrophy.
2.MaterialsandMethods
2.1. Drugs and Chemicals. Unless otherwise stated, all
reagents were of analytical grade and purchased from Sigma-
Aldrich (Tokyo, Japan). DNR was kindly donated by Meiji
Seika Ltd (Tokyo, Japan). Carvedilol was donated by Daichi-
Sankyo Pharmaceutical (Tokyo, Japan).
2.2. Animals and Medication. Eight-week-old male Sprague-
Dawley rats were obtained from Charles River Japan Inc.
(Kanagawa, Japan). On day 0, each animal received a single
intravenous injection of DNR at a dose of 3mg/kg (i.v.).
The drug was administered in three equal injections at
48-hour intervals for a period of a week to achieve an
accumulative dose of 9mg/kg, which is well documented to
achievecardiotoxicity[13,16].Twenty-twoDNR-treatedrats
were randomly divided into two groups and received oral
administration of carvedilol (30mg/kg/day; group Carv; n =
10) or vehicle (group DNR; n = 12). Age-matched rats were
injected with corresponding volumes of 0.9% NaCl and used
as a control (group C; n = 5). Administration of carvedilol
was started on the same day as DNR administration and
continued for 5 additional weeks after cessation of DNR
administration(6weekstotalperiod).Throughoutthestudy,
all animals were cared for in accordance with the guidelines
ofourinstituteandtheGuideforCareandUseofLaboratory
Animals published by the US National Institutes of Health.
2.3. Cardiac Function Measurements. After the end of the
study period (6 weeks), the body weight (BW) was mea-
sured, and rats were anesthetized with 2% halothane in
O2 and subjected to surgical procedures. Left ventricular
(LV) function analysis was carried out using hemodynamic
and echocardiography measurement. After the instrumenta-
tion, the concentration of halothane was reduced to 0.5%
to record steady-state hemodynamic data. Hemodynamic
parameters such as mean blood pressure (MBP), peak LV
pressure (LVP), LV end-diastolic pressure (LVEDP), and the
rate of intraventricular pressure rise and decline (±dP/dt)
were recorded as previously described [17].
Two-dimensional echocardiographic studies were per-
formed under 0.5% halothane anesthesia using an echocar-
diographic machine equipped with a 7.5-MHz transducer
(SSD-5500; Aloka, Tokyo, Japan). M-mode tracings were
recordedfromtheepicardialsurfaceoftherightventricle;the
short axis view of the left ventricle was recorded to measure
the LV dimension in diastole (LVDd) and LV dimension in
systole (LVDs). LV fractional shortening (FS) and ejection
fraction (EF) were calculated and expressed as percentages.
The study was performed in a blinded manner.
2.4. Histopathological Analysis. After the measurement of
echocardiographic parameters, hearts were excised and
weighed immediately (HW), and its ratio to BW (HW/BW)
was calculated. Half of each heart was immediately snap-
frozen in liquid nitrogen for subsequent protein extraction
and enzymatic assays. The remaining excised hearts were
cut into about 2-mm-thick transverse slices and ﬁxed in
10% formalin. After being embedded in paraﬃn, several
transverse sections were obtained from the ventricle and
stained with hematoxylin and eosin (HE) and Azan-Mallory
to demonstrate interstitial edema, vacuolization, degenera-
tion ofcardiac ﬁbers,andhypertrophyand ﬁbrosisin cardiac
tissues, respectively. The area of ﬁbrosis (blue color) was
quantiﬁed with a color image analyzer (Mac Scope; Mitani
Co., Fukui, Japan).
2.5. Protein Analysis by Western Blotting. Protein lysate was
prepared from heart tissues as described previously [18].
The total protein concentration in samples was measured
by the bicinchoninic acid method [19]. For the deter-
mination of protein levels of atrial natriuretic peptide
(ANP), transcription factor GATA-4, protein kinase C-alpha
(PKC-α), osteopontin (OPN), and tumor growth factor-
β1( T G F - β1) equal amounts of protein extracts (30μg)
were separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (Bio-Rad, CA, USA) and transferred
electrophoreticallytonitrocellulosemembranes.Membranes
were blocked with 5% nonfat dry milk in Tris-buﬀered saline
Tween (20mM Tris, pH7.6, 137mM NaCl, and 0.1% Tween
20). All the antibodies were purchased from Santa Cruz
Biotechnology Inc. (CA, USA) and used at a dilution of
1:1000. Themembranewasincubatedovernight at4◦Cwith
the primary antibody, and the bound antibody was visual-
ized using the respective horseradish peroxidase secondaryISRN Pharmacology 3
antibodies (Santa Cruz Biotechnology Inc.) and chemilumi-
nescence developing agents (Amersham Biosciences, Buck-
inghamshire, UK). The level of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was estimated in every sample to
check for equal loading of samples. Films were scanned, and
band densities were quantiﬁed with densitometric analysis
using Scion Image program (Epson GT-X700, Tokyo, Japan).
All values were normalized by setting the density of normal
samples as 1.0.
2.6. Statistical Analysis. Data are presented as mean ±
SEM and were analyzed using one-way analysis of variance
(ANOVA) followed by Tukey or Bonferroni methods for
post hoc analysis and two-tailed t-test when appropriate. A
value of P<. 05 was considered statistically signiﬁcant. For
statistical analysis, GraphPad Prism 5 software (San Diego,
C A ,U S A )w a su s e d .
3. Result
3.1. General Toxicity. The general appearance and mortality
ofanimalswererecordedduring thetimecourseofthestudy.
In the control group, no premature mortality was observed,
and BWs were signiﬁcantly increased during the experiment
as compared with the initial values (408 ± 1.6 versus 538 ±
6.6g;P<. 05). On the other hand, premature death of six
out of twelve animals (50%) with the presence of signiﬁcant
decrease in the BW was observed in DNR-treated rats (430±
12 versus 379 ± 9g; P<. 05 beginning vs end of study).
Furthermore, in prematurely dead animals, a necropsy
examination revealed a massive hydrothorax, ascites, and
gastrointestinal bleeding. In addition, in comparison with
the control group, the HW/BW was found to be signiﬁcantly
increasedinthisgroup(2.9±0.06versus2.3±0.02g/kg,resp.,
P<. 05).
The decrease in BW was also found in the treatment
group as compared with the initial values (423 ± 7.9v e r s u s
405 ± 21g; beginning versus end). The premature death
was less when compared with DNR group. Two of ten
animals (20%) were died during the time course of the
study. Although carvedilol treatment tended to decrease the
HW/BW compared with that in group DNR, the eﬀect did
not attain statistical signiﬁcance (2.4 ± 0.02 versus 2.9 ±
0.06g/kg, P>. 05).
3.2. Eﬀect of Carvedilol on Myocardial Functions. LVEDP was
signiﬁcantly higher (10.7 ± 0.3v e r s u s7 .5 ± 0.9mmHg, P<
.05), and LVP and ±dP/dt were signiﬁcantly lower in group
DNR than in control group (111 ± 7 versus 124.3mmHg,
P<. 05; 4800 ± 345 versus 6813 ± 541mmHg/s, P<. 05;
4135 ± 365 versus 7290 ± 775mmHg/s, P<. 05, resp.),
indicating systolic and diastolic dysfunction in DNR rats.
Carvedilol treatment improved the myocardial dysfunction
by signiﬁcant reduction in LVEDP (8.2 ± 1.2v e r s u s1 0 .7 ±
0.3mmHg, P<. 05) and elevation in the LVP and +dP/dt
(120.5±11 versus 111±7mmHg, P<. 05; 6229±581 versus
4800 ± 345mmHg/s, P<. 05, resp.) compared with those in
group DNR.
Echocardiographic data revealed that LV systolic func-
tion, as assessed by FS and EF, was reduced signiﬁcantly in
group DNR compared with that in control group (29.1±1.3
versus 42.8±1.7%,P<. 05;and59.6±1.4v ersus78.9±1.8%,
P<. 05, respectively). The reductions in both FS and EF
weresigniﬁcantly attenuated in group Carv (38.8±3.5v e r s u s
29.1 ± 1.3%, P<. 05; 73.6 ± 4.4v e r s u s5 9 .6 ± 1.4%, P<. 05,
resp.). In addition, LVDd and LVDs were also enlarged in
group DNR compared to group control (6.7 ± 0.5v e r s u s
8.03 ± 0.3mm, P<. 05; 5.3 ± 0.2v e r s u s4 .4 ± 0.3mm,
P<. 05, resp.). The increase in both LVDd and LVDs were
signiﬁcantly attenuated in group Carv (7.05 ± 0.4v e r s u s
8.03±0.3mm,P<. 05;4.9±0.5v e rs us5.3±0.2mm,P<. 05,
resp.).
3.3. Eﬀect of Carvedilol on Cardiac Histopathology. Histo-
logical changes in heart were evaluated, and the result
is presented in Figure 1. Normal histology was seen in
the control group (Figure 1(a)). On the other hand, there
were several histological changes found in the DNR group
(Figure 1(a)). Qualitatively, DNR-induced cardiac damage
was recognized by the presence of marked interstitial edema,
perinuclearvacuolization,disorganization,anddegeneration
of the myocardium. The damage in the form of lesions was
rarely seen in the group treated with carvedilol compared
with those in the DNR group (Figure 1(a)).
Myocyte diameter was increased in group DNR com-
pared with that in group C and reduced in group Carv
(Figure 1(b)). Group DNR showed higher % of ﬁbrosis
(P<. 05 versus group C); while in group Carv, ﬁbrosis was
signiﬁcantly reduced (P<. 05 versus group DNR) (Figures
1(c) and 1(d)).
3.4. Eﬀect of Carvedilol on Myocardial Protein Expression
of ANP, GATA-4, TGF-β1,P K C - α, and OPN Assessed by
Western Blotting. Rats treated with DNR alone had an up-
regulated expression of ANP, TGF-β1, PKC-α, and OPN in
comparison with those in control group, and the treatment
with carvedilol signiﬁcantly reversed these changes (Figures
2(a), 2(b), 2(d), 2(e),a n d2(f)). Moreover, myocardial
protein expression of GATA-4 was decreased in group
DNR compared with that in group Control, and carvedilol
treatment signiﬁcantly attenuated the decrease in GATA-4
(Figures 2(a) and 2(c)).
4. Discussion
In this study, repeated DNR administration resulted in
increased mortality, which was accompanied by the symp-
toms of general toxicity. Hemodynamic and echocardiog-
raphy measurements revealed a progressive decline in LV
systolic and diastolic functions. Cotreatment with carvedilol
was capable to protect the animals from cardiac dysfunction,
and as a consequence the mortality rate was reduced. These
ﬁndings illustrate the excellent cardioprotective potential of
carvedilol, and the overall result is well in line with the
outcomes of preclinical studies and clinical trials [13–15].4 ISRN Pharmacology
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Figure 1: (a) Hematoxylin and eosin staining of the cross-sectional tissue slices of hearts depicting interstitial edema, vacuolization, and
degeneration of cardiac ﬁbers (X200). (b) Hematoxylin and eosin staining of the cross-sectional tissue slices of hearts depicting cardiac
hypertrophy (X400), (c) Azan-Mallory staining for ﬁbrosis of the cross-sectional tissue slices of hearts. Fibrosis is indicated by the blue area
as opposed to the red myocardium (X200). (d) Bar graph showing % ﬁbrosis in each experimental group. Each bar represents mean ±
S.E.M. Group control (C) age-matched normal rats; group DNR, DNR-treated rats administered with vehicle; group Carv, DNR-treated rats
administered with carvedilol (30mg/kg/day).
∗P <. 05 versus group Control; #P <. 05 versus group DNR.
Cardiac hypertrophy, deﬁned as an increase in cardiomy-
ocyte size, is an adaptive response to a number of intrin-
sic (e.g., mutations of sarcomeric contractile proteins in
familial hypertrophic cardiomyopathy) and extrinsic stimuli
(e.g., hypertension). It is characterized by increased protein
synthesis, sarcomeric reorganization, and re-expression of
fetal regulatory genes. Prolonged pathological cardiac hyper-
trophy is a major cardiovascular endpoint and is strongly
associatedwitharrhythmias,heartfailure,andsuddendeath.
In the present study, rats treated with DNR alone had
developed cardiac hypertrophy and LV dilatation, which is
evidenced by an increase in myocardial expression of ANP,ISRN Pharmacology 5
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Figure 2: Myocardial expressions of ANP, GATA4, TGF-β1, PKC-α, and OPN. (a) Representative western blots showing speciﬁc bands for
ANP, GATA4, TGF-β1, PKC-α, OPN, and GAPDH as an internal control. Equal amounts of protein sample (30μg) obtained from whole
ventricular homogenate were applied in each lane. These bands are representative of ﬁve separate experiments. (b–f) Densitometric data of
protein analysis. The mean density values of ANP, GATA4, TGF-β1, PKC-α, and OPN were expressed as ratios relative to that of GAPDH.
Each bar represents mean ± S.E.M. Group control (C), age-matched normal rats; group DNR, DNR-treated rats administered with vehicle;
group Carv, DNR-treated rats administered with carvedilol (30mg/kg/day).
∗∗P <. 01 versus group Control; ##P <. 01 versus group DNR.
that is documented to be elevated in cardiac hypertrophy
or failure [20, 21], increase in myocyte size, HW/BW,
LVDd, and LVDs, and decrease in FS and EF. Moreover,
the myocardial expression of PKC-α, a gene related to
myocardial hypertrophy [22], also increased in DNR rats.
In the carvedilol-treated rats, a signiﬁcant reduction of
myocardial expression of ANP and PKC-α, myocyte size,
HW/BW, LVDd, and LVDs and increase in the FS and EF has
been observed. The above results indicated that carvedilol
improves myocardial function and attenuates abnormal
cardiac hypertrophy caused by DNR. To the best of our
knowledge, this is the ﬁrst study to perform the eﬀect of
carvedilol against cardiac hypertrophy induced by DNR.
Anthracycline (doxorubicin) is thought to induce cardiac
hypertrophy, a dose-limiting side eﬀect, by the formation of
free radicals and lipid peroxidation [23]. Previously, we have
reported that DNR caused activation of NADPH oxidase
subunits by increasing the myocardial levels of p47phox
and p67phox, in addition to the increased malondialdehyde
level and decreased glutathione peroxidase activity [13].
Carvedilol treatment signiﬁcantly attenuated those changes
[13]. Thus, we speculated that the ability of carvedilol to6 ISRN Pharmacology
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Figure 3: The possible mechanism by which carvedilol aﬀorded protection against DNR-induced cardiomyopathy.
attenuate the cardiac hypertrophy caused by DNR in this
study is through its ability to reduce the oxidative stress in
DNR rats.
In the present study, the western blotting data showed
that the DNR caused the signiﬁcant reduction of myocardial
expression of GATA-4, and cotreatment with carvedilol
attenuated this reduction. The GATA-4 transcription factor
is an important regulator of cardiac muscle cells [24,
25], and increased activities of GATA transcription fac-
tors could exert unwanted clinical manifestation such as
cardiac hypertrophy [26] .K i me ta l .[ 27] reported that
anthracyclines can downregulate GATA-4 activity, and the
mechanism of anthracyclines-induced cardiotoxicity may
involve the downregulation of GATA-4 and the induction
of apoptosis [27]. It is well established that carvedilol has
antiapoptotic properties [28] and the inhibition of apoptosis
as an important target for eﬀective cardioprotection against
antharcycline cardiotoxicity [29] .R e c e n t l y ,w eh a v er e p o r t e d
that DNR caused apoptosis by increasing the number of
positive apoptotic cells, decreased myocardial level of Bcl-2,
and increased myocardial level of caspase-7, and carvedilol
treatment attenuated these changes [13]. Therefore, it is
possible that the ability of carvedilol to increase the myocar-
dial expression of GATA-4 in DNR rats is owing to its
antiapoptotic properties.
OPN, a key component of the extracellular matrix, is
associated with the ﬁbrotic process during tissue remodeling
[30]. Recent studies indicate that OPN expression is oblig-
atory for the formation of pathological myocardial ﬁbrosis
in rodents [31] and strongly associated with LV hypertrophy
[32]. However, the role of OPN in anthracycline-induced
cardiomyopathy has not been elucidated. In this study, we
have shown that OPN myocardial expression was enhanced
in DNR rats compared with that in control group. It is of
interest that, in the present study, carvedilol could suppress
the enhanced expression of OPN in DNR rats along with
decreased myocyte size (Figure 1(b)) and area of myocardial
ﬁbrosis (Figures 1(c) and 1(d)). We hypothesize that the
increased expression of OPN in this animal model is due
to the oxidative stress, since there is cross-talk between
the level of OPN and oxidative stress in patients with
heart diseases [33]. In addition, the eﬀect of carvedilol on
the prevention of ﬁbrosis and hypertrophy might partially
be mediated through the inhibition of OPN expression.
However, this hypothesis is still speculative, and further
evidence is necessary to support it.
Our earlier reports showed that carvedilol reduced the
cardiac ﬁbrosis and inhibited the progression of heart failure
inratswithdilatedcardiomyopathy[17,34].Previousstudies
reported that carvedilol could prevent myocardial ﬁbrosis in
hamstermodelsofprogressivecardiomyopathy[35].Itiswell
established that TGF-β1 is a ﬁbrogenic cytokine which is an
important modulator in the ventricular remodeling process
[36], and carvedilol treatment reduced the expression of
TGF-β1[ 37]. Similar with those above results, in this
study, cotreatment with carvedilol also led to the reduction
in myocardial ﬁbrosis as evident from decreased area of
myocardial ﬁbrosis with Azan-Mallory staining (Figure 1(c))
and reduced myocardial expression of TGF-β1 (Figures 2(a)
and 2(d)). These results may account for the preventive
eﬀects of carvedilol on DNR-induced cardiomyopathy and
propose a new eﬀect of this drug on suppression of TGF-β1.
In conclusion, the present study indicates that carvedilol
increases survival rate, prevents systolic and diastolic dys-
function, and attenuates myocardial ﬁbrosis and hypertro-
phy in DNR-induced cardiomyopathic rats. The possible
mechanism(Figure 3)bywhichcarvedilolcanreduceﬁbrosis
in DNR rats is decreasing oxidative stress-related factorsISRN Pharmacology 7
and further decreasing the levels of TGF-β1 and OPN. In
addition, carvedilol inhibited hypertrophy (as shown by
decreased myocardial ANP and PKC-α levels) possibly via its
antioxidant properties. Moreover, carvedilol also attenuated
the reduction in GATA-4 level and prevented myocardial
apoptosis. All these ﬁndings might explain the ability of
carvedilol to prevent cardiomyopathy induced by DNR. The
resultsofthe presentstudy add the availableevidenceson the
cardioprotective action of carvedilol when associated with
anthracyclines and explain the mechanisms underlying the
beneﬁts of their coadministration.
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